

Nemaura Medical Inc

10:28 17 Dec 2019

Nemaura Medical teams up with Changing Health to battle Type 2 diabetes in UK and Ireland

Nemaura Medical Inc (NASDAQ:NMRD), the maker of the SugarBEAT continuous glucose monitor, announced Tuesday it is teaming with Changing Health to improve the management, reversal and prevention of Type 2 diabetes starting in the UK and Ireland.

UK-based Changing Health is a provider of digital coaching services to the National Health Service England, aimed at the prevention or reversal of Type 2 diabetes.

The partnership will utilize daily glucose trend data provided by Nemaura's non-invasive sugarBEAT monitor, combined with Changing Health's evidence-based digital health coaching solution -- which has been the subject of multiple peer-reviewed journal articles demonstrating proven outcomes in the reduction of HbA1c (average blood sugar levels) and weight loss.

READ: Nemaura unveils Type 2 diabetes management app as companion to its SugarBEAT glucose monitor

The collaboration with Changing Health is one of a number of initiatives Nemaura is embarking upon, as it seeks to improve how people with diabetes and prediabetes can manage, reverse and prevent Type 2 diabetes through its BEAT diabetes health subscription service coupled with sugarBEAT across the digital health, wearable health-tech and diabetes sectors.

"We are delighted to enter into this collaboration with Changing Health, a leading global force in behavioral change programs," said Nemaura CEO Dr Faz Chowdhury in a statement.

"This collaboration is part of our continued commitment to add further services to our BEAT diabetes program aimed at improving management of diabetes and reversing or preventing Type 2 diabetes."

Mike Trenell, founder and chairman of Changing Health, said the collaboration "will become a disruptive force" in the medical-technology space.

"Empowering people with Type 2 diabetes with a real-time view of how they're managing their condition each day is the best motivator there can be, and we're looking forward to working with Nemaura to create positive behavioral change at scale," he said.

The Loughborough, England company's SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. What's unique about SugarBEAT is its skin-patch technology, which the company said offers for painless glucose management.


Nemaura's stock recently traded up less than 1% to \$4.40 a share in New York.

Contact the author: patrick@proactiveinvestors.com

Price: 7.15

Market Cap: \$148.78 m

1 Year Share Price Graph



June 2019 December 2019 June 2020

Share Information

Code: NMRD

Listing: NASDAQ

52 week	High	Low
	10.9	2.5

Sector: Medical technology & services

Website: www.nemauramedical.com

Company Synopsis:

Nemaura Medical Inc. is a medical technology company which has developed sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) designed to improve glucose management for all people with diabetes and pre-diabetics.

action@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Nemauro Medical Inc named herein, including the promotion by the Company of Nemauro Medical Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).